Concerning the mechanisms specific to ADRs and sex discrepancies, both Tralokinumab and Lebrikizumab, monoclonal antibodies targeting IL-13, have been demonstrated to correlate with elevated risks of conjunctivitis as discerned in phase 2 and 3 clinical trials (Simpson et al., 2018; Wollenberg et al., 2019). This evidence concerns the gene IL13 and conjunctivitis.